Skip to content

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

Menu

Home
ABOUT
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
Access your profile
Login

Menu

Home
ABOUT
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
Access your profile
Login

[denovo_breadcrumbs]

The EMPEROR clinical trials – Further guidance for today’s clinical practice

Questionnaire

To access this module, please register or login:

Login or Register

The EMPEROR clinical trials – Further guidance for today’s clinical practice The EMPEROR clinical trials – Further guidance for today’s clinical practice

Time limit: 0

Questionnaire Summary

0 of 10 Questions completed

Questions:

Information

You have already completed the questionnaire before. Hence you can not start it again.

Questionnaire is loading…

You must sign in or sign up to start the questionnaire.

You must first complete the following:

Results

Questionnaire complete. Results are being recorded.

Results

0 of 10 Questions answered correctly

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Regrettably, you failed to achieve the 70% pass mark required by the accrediting HPCSA.
Please try again!
For queries, please contact cpd@denovomedica.com
Congratulations on successfully completing our FREE CPD module!
Please click on button just above to download and print your CPD certificate. Alternatively, an email will be sent to you with the link to your profile, there you will find all your CPD certificates to download.
For HPCSA members, please allow 5-10 days for the CPD activity to reflect on your HPCSA profile.

1
2
3
4
5
6
7
8
9
10

Current
Review
Answered
Correct
Incorrect

Question 1 of 10
1. Question
This questionnaire saves your responses automatically every 20 seconds if you are interrupted while answering.
1. The latest ESC Guidelines on Heart Failure recommend the use of SGLT-2 inhibitors for HFrEF:
A. In all patients
B. In diabetic patients only
C. Only in diabetic patients with frequent hospital admissions
Question 2 of 10
2. Question
2. Which statement is correct? The ACC Guidelines (2022) and ESC Guidelines (2021) recommendations regarding HFpEF are:
A. Both recommended SGLT-2 inhibitors for diabetic patients to decrease HF hospitalisation
B. Both recommend SGLT-2 inhibitors to rescue CV mortality
C. Both recommendations are at level 1
Question 3 of 10
3. Question
3. The current approach of recommending foundational therapy for patients with HF to continue with this therapy as long as possible is based on randomised double-blind large-scale trials.
A. True
B. False
Question 4 of 10
4. Question
4. The unique aspect of the EMPEROR-Reduced and EMPEROR-Preserved trials compared to other landmark trials is:
A. They include diabetic and non-diabetic patients
B. It has a pre-set protocol for evaluating effects of withdrawal
Question 5 of 10
5. Question
5. Which statement is correct? The number of patients included in this blinded withdrawal study of empagliflozin:
A. Was almost 4 000 patients
B. Represented 74% of the total number of patients recruited in both EMPEROR trials
Question 6 of 10
6. Question
6. How long had the patients been treated with empagliflozin for prior to withdrawal?
A. Less than 2 years
B. 1-3 years
C. More than 3 years
Question 7 of 10
7. Question
7. Withdrawal of empagliflozin resulted in:
A. An increase in CV event risk
B. A drop in Quality-of-Life self-assessment
C. An increase in systolic BP and an increase in body weight
D. All of the above
Question 8 of 10
8. Question
8. The increase in CV event risk on withdrawal was mainly driven by an increase in heart failure hospitalisation.
A. True
B. False
Question 9 of 10
9. Question
9. This study comparing withdrawal of empagliflozin treatment to placebo-withdrawal showed that:
A. The benefits of empagliflozin in the treatment of HF were not maintained after withdrawal of empagliflozin
B. The extent of the decrease on withdrawal mirrored the extent of benefit
C. Tolerance did not develop to empagliflozin after 1-3 years of treatment
D. Withdrawal of therapy may have deleterious consequences
E. All of the above
Question 10 of 10
10. Question
10. What are the pillars of the guidelines for foundational therapy for chronic heart failure?
A. ACE inhibition/ARNI
B. Betablockade
C. Mineralocorticoid antagonism
D. SGLT-2 inhibitors
E. All of the above
F. A, B and D

All Rights Reserved 2025 © deNovo Medica (Pty) Ltd in South Africa. The content on this website is intended for healthcare related professionals unless stated otherwise.

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Login

Accessing this module requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?